Company KaloBios Pharmaceuticals Inc Nasdaq

US48344T1007

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Biopharmaceuticals

Inactive Instrument

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 12	Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc.	CI
Mar. 08	Final DIP Financing Approved for Humanigen, Inc.	CI

Humanigen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The Company has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.

USD in Million	2021	Weight	2022	Weight	Delta
Pharmaceutical Products 100.0 %	4	100.0 %	3	100.0 %	-30.07%

USD in Million	2021	Weight	2022	Weight	Delta
United States 100.0 %	4	100.0 %	3	100.0 %	-30.07%

Managers	Title	Age	Since
Cameron Durrant CEO	Chief Executive Officer	63	16-01-06
Omar Ahmed CTO	Chief Tech/Sci/R&D Officer	-	-
Dale B. Chappell CTO	Chief Tech/Sci/R&D Officer	53	20-07-05
Bob Atwill PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Cameron Durrant CEO	Chief Executive Officer	63	16-01-06
Dale B. Chappell CTO	Chief Tech/Sci/R&D Officer	53	20-07-05
Ronald Barliant BRD	Director/Board Member	78	16-01-06
Rainer Boehm BRD	Director/Board Member	63	18-02-11
Omar Ahmed CTO	Chief Tech/Sci/R&D Officer	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	119,080,135	106,754,128 ( 89.65 %)	0	89.65 %

Name	Equities	%	Valuation
Black Horse Capital Management LLC 9.866 %	11,747,937	9.866 %	117 $
Telemetry Investments LLC 0.3947 %	470,000	0.3947 %	5 $
Ronald Barliant 0.0755 %	89,870	0.0755 %	1 $
Rainer Boehm 0.0714 %	84,986	0.0714 %	1 $
Triumph Capital Management 0.0143 %	17,000	0.0143 %	0 $
Edward Jordan 0.0105 %	12,500	0.0105 %	0 $
Cheryl Buxton 0.003665 %	4,364	0.003665 %	0 $
Auriga Global Investors Sociedad de Valores SA (Invt Mgmt) 0.000840 %	1,000	0.000840 %	0 $
Allianz Global Investors GmbH (France) 0.000311 %	370	0.000311 %	0 $
Yi Li Xie 0.000000 %	0	0.000000 %	- $

Humanigen, Inc.

830 Morris Turnpike 4th floor

07078, Essex County

+973 200 3100

http://www.humanigen.com

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-5.99%	83.66B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.41B
BIOGEN INC.	-24.88%	28.26B
UCB	+53.61%	24.53B
BIOMARIN PHARMACEUTICAL INC.	-8.08%	16.82B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-33.74%	13.39B
INCYTE CORPORATION	-16.63%	11.75B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.19%	11.69B
SWEDISH ORPHAN BIOVITRUM AB	-2.25%	8.13B

Biopharmaceuticals